Literature DB >> 23948508

In vivo feasibility study of ultrasound potentiated collagenase therapy of chronic total occlusions.

David E Goertz1, Amandeep S Thind, Raffi Karshafian, Michelle Ladouceur, Cari M Whyne, F Stuart Foster, Bradley H Strauss.   

Abstract

Arterial chronic total occlusions (CTOs) pose considerable challenges for percutaneous interventions, due primarily to the presence of stiff proximal fibrous caps (PFCs) which act as a barrier to the penetration of guide wires. A new approach under development for improving the success rate of guide wire crossing in CTOs is to employ collagenase to degrade the mechanical integrity of the PFCs. This has been shown to be feasible in preclinical work and in a Phase 1 clinical trial. In a recent study we demonstrated using ex vivo experimental CTO specimens that ultrasound-stimulated microbubbles (USMBs) could potentiate the effects of collagenase and result in increased mechanical degradation of the PFCs of CTOs. Here we report the results of the first in vivo study examining the feasibility of this approach, which demonstrates that the force required to puncture through the PFCs of CTOs is reduced with combined USMB+collagenase treatments relative to collagenase only treatments. This approach has the potential to further improve the efficacy of the emerging technique of collagenase facilitation of percutaneous interventions for CTO.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Chronic total occlusion; Microbubbles; Percutaneous intervention; Therapeutic ultrasound

Mesh:

Substances:

Year:  2013        PMID: 23948508     DOI: 10.1016/j.ultras.2013.07.014

Source DB:  PubMed          Journal:  Ultrasonics        ISSN: 0041-624X            Impact factor:   2.890


  1 in total

Review 1.  The Canadian Contribution to Science, Techniques, Technology, and Education in Chronic Total Occlusion Percutaneous Coronary Intervention.

Authors:  Luiz F Ybarra; Christopher E Buller; Stéphane Rinfret
Journal:  CJC Open       Date:  2020-09-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.